Deep Intelligence Across Industries

Company Headquarters: Venice, Italy Founded: 2001 Company Working: Xeptagen SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early-stage cancer and the proprietary platform technology Combinatorial Proteomic, Xeptagen SpA has discovered predictive, prognostic, and early-response tumor markers that lead to earlier and much more accurate detection of developing carcinomas.

Company Headquarters: Oxford, UK Founded: 2012 Company Working: Perspectum Diagnostics Ltd (Perspectum) is engaged in developing technologies to diagnose and measure liver diseases based on magnetic resonance imaging (MRI). The company offers LiverMultiScan, a software product that provides objective and quantitative information about the patient’s liver. Moreover, the company provides its LiverMultiScan software to several treatment and research centers across the globe.

Company Headquarters: Washington, US Founded: 1989 Company Working: Pacific Biomarkers is a company providing biomarker testing and specialty biomarker development services, supporting pharmaceutical, biotech, and in-vitro diagnostic (IVD) manufacturing companies through preclinical and Phase I-IV studies of drug and IVD development. The company has over 300 fully CLIA validated assays and an extensive network of scientific, regulatory, and technology expertise. The company operates as a subsidiary of Ampersand Capital.

Company Headquarters: Bizkaia, Spain Founded: 2002 Company Working: One Way Liver, SL (OWL) is a biotechnology company engaged in the field of metabolomics. The company has two business segments, namely, diagnostics products and R&D services. OWL also develops diagnostic markers for highly prevalent diseases. The company uses its expertise in metabolomics and lipidomics to provide services to the pharmaceutical industries, food industries, research centers, biotechnology companies, and contract research organizations.

Company Headquarters: California, US Founded: 2008 Company Working: NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. The company is focused on understanding chronic diseases to develop transformative therapeutics for patients. NGM Biopharmaceuticals and Merck have an ongoing broad, multi-year strategic collaboration to discover, develop, and commercialize novel biological therapies across a wide range of therapeutic areas.

Company Headquarters: Paris, France Founded: 2008 Company Working: Enterome develops disease management solutions. The company focuses on developing biomarkers, companion diagnostics, and therapeutics. It also develops specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and to use as companion diagnostics; and drugs for the treatment of various microbiome-related diseases, such as inflammatory bowel diseases, metabolic diseases, and other related disorders. The company is based in Paris, France with another office in Cambridge, US

Company Headquarters: Lincoln, Nebraska, US Founded: 2010 Company Working: Celerion provides clinical research and delivers applied translational medicine services for pharmaceutical and biotechnology companies. These services include clinical research, data management and biometrics, clinical data sciences, biostatistics, and drug development services. The company has operations in major countries in North America, Europe, and Asia-Pacific.

Company Headquarters: Paris, France Founded: 1888 Company Working: BioPredictive is a biopharmaceutical company involved in designing and marketing a wide variety of non-invasive diagnostic tests for liver diseases. The company offers diagnostic tests such as FibroMax, Elasto-FibroTest, and HCV-GenoFibroTest. Its flagship product is the Elasto-FibroTest, which is the first diagnostic test for the liver that combines the results of the FibroTest- ActiTest for the determination of the level of necroinflammatory activity with an elastography result, directly from the user’s smartphone. The company has distribution channels throughout the world.

Hewlett Packard Enterprise Company (HPE) is one of the leading providers of technology solutions to increase customers' traditional information technology. The company operates through three business segments, namely enterprise group (EG), financial services (FS), and corporate investments. EG segment offers a wide range of enterprise technology solutions for the next generation of applications, web services, and user experiences. It offers servers, storage, networking, and technology services. The company also offers networking devices such as switches, routers, wireless local area network (WLAN), and network management products. These networking devices provide consistent solutions that can be implemented in data centers, campuses, and offices and deliver software-defined networking (SDN) and unified communications capabilities. HPE also offers support and consulting services. The support services offerings cover various levels of customer support requirements and include HPE Foundation Care, HPE Proactive Care, HPE Datacenter Care, and Lifecycle Event services. HPE has a presence in the Americas, Asia-Pacific, Europe, and the Middle East & Africa.

Company Headquarter: United States Founded: 2014 Workforce: 10+employees Company Working: LENA is a company dedicated to women health and wellness, is making strides towards the same with its product Lena cup. It has been voted as the best cup for beginners according to customers review. They also have sensitive variant of cup designed especially for the beginners that prevents vaginal dryness and discomforts associated with first use. Though it provides the product at a reasonable price than its competitors, it has taken care to maintain the quality standards.

Company Headquarter: Czech Republic Founded: 1998 Workforce: 100+employees Company Working: Yuuki launched its first menstrual cup in 2007 after extensive research for more than eight years. Since then, it has expended a lot in research and development to improvise on product designing and customize it according to the use. This company has an added advantage of designing products for sportswomen

Company Headquarter: Spain Founded: 2011 Workforce: 10+ Company Working: Ruby Cup a part of Ruby Life Ltd. and is a social business founded in 2011. Ruby Life sells and donates menstrual cups, naming their product as Ruby Cup. Ruby Cup strives to improve the menstrual hygiene for women and girls, making a positive change to their lifestyle.

Company Headquarter: United States Founded: 1992 Workforce: 50 + employees Company Working: The company focusses on women’s health. It has product lines for birth control as well as menstruation.

Company Headquarter: United States Founded: 2011 Workforce: 50+ employees Company Working: Anigan is working religiously for a decade to provide worry-free menstruation services to women. It has several ranges of products dedicated to the worry-free periods business segment. It offers 100% safe and reusable menstruation range of products such as a stain-free period panty, period kits, menstrual cups, etc.

Company Headquarter: Canada Founded: 2002 Workforce: ~50 Company Working: Diva International Inc. has been working dedicatedly for more than 15 years towards women hygiene. It is the only ISO 13485:2003 certified menstrual cup manufacturer company. It markets products to more than 29 countries. The company was ranked 103 on the 2017 report of PROFIT 500 ranking of Canada’s fastest-growing companies. The annual sales of the company are above USD 20 million.

Company Headquarter: United States Founded: 1987 Workforce: 50 Company Working: The Keeper, Inc. is a woman-centric business company. This is one of the most recognized names in the menstrual cup company. The company is working hard to reduce the environmental footprint while working towards personal care products for women.

Company Headquarter: Finland Founded: 2005 Workforce: 50+ employees Company Working: Lunette is a finish-based company whose subsidiary company Lune Group Oy Ltd is a leading manufacturer of menstrual cups. It stresses on building eco-friendly products preferably from recyclable materials because of its policy of sustainable development. The company has a great market presence in Europe.

Citigroup is the most internationally wired of the U.S. money-centre banks and, after five years of deliberate contraction, the most narrowly defined it has been in a generation. Its franchise rests on a payments, clearing and custody utility — Services — that no domestic peer can replicate at comparable scale, wrapped around a top-three markets business, a rebuilt investment bank, a wealth platform in mid-turnaround, and a large but strategically awkward U.S. cards book. Jane Fraser's tenure has been defined less by growth than by subtraction: fourteen international consumer markets exited, Banamex sold down to a minority stake, Russia divested, five management layers removed. The payoff arrived in 2026. First-half revenue of USD 49.4 billion and 13% RoTCE put Citi at the top of a target range it once expected to reach only in 2028. The open question is no longer whether the franchise works, but whether returns can close a still-wide gap to JPMorgan and Morgan Stanley. --- ### The company's own characterisation Citigroup describes itself in its FY2025 Form 10-K as a global diversified financial services holding company whose businesses provide consumers, corporations, governments and institutions with a broad but focused range of financial products and services — consumer banking and credit, corporate and investment banking, securities brokerage, trade and securities services, and wealth management. In its 2026 press releases the firm uses a tighter formulation: a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management, and a valued personal bank in its home market of the United States. That three-part vision statement is the organising principle of the current strategy and was reaffirmed verbatim at the May 2026 Investor Day. ### Independent characterisation Citi is best understood as four businesses of very different economic character bolted to a single balance sheet, plus a large run-off estate. **First, an infrastructure toll-road.** Treasury and Trade Solutions and Securities Services together form the Services segment, which processes payments in 94 markets across more than 300 clearing systems, safeguards USD 35 trillion of assets under custody and administration (2Q26, preliminary), and clears roughly 46 million U.S.-dollar payment instructions per quarter. Citi told investors at its 2026 Investor Day that it moves approximately USD 6 trillion of payments daily across 180 countries. This is a scale-and-network business with high switching costs, deposit-funded economics, and a 30.9% RoTCE in 2Q26 — the highest-returning material business in the group and the reason Fraser calls it the "crown jewel." **Second, a flow-trading and financing operation.** Markets earns from bid-offer capture, prime brokerage financing spreads, and securitised financing. It is capital-intensive, cyclical, and — unusually for Citi — a business where the firm holds a defensible number-two position in fixed income but only roughly 5% share in equities, which management has identified as its principal share-gain opportunity. **Third, a fee-and-advice complex.** Banking (advisory, equity and debt underwriting, corporate lending) and Wealth (Citigold and Retail Banking, Private Bank, Wealth at Work) monetise relationships rather than balance sheet. Both were sub-scale relative to peers at the start of the transformation and both are now inflecting: Banking net income rose 276% year over year in 2Q26; Wealth revenues have risen for nine consecutive quarters. **Fourth, a U.S. consumer credit book.** U.S. Consumer Cards is a spread-and-fee lender with partner-payment economics, dominated by two co-brand relationships (Costco and American Airlines) plus a proprietary card portfolio. Its returns are good through the cycle (low-20s RoTCE target) but its earnings are credit-cycle-levered and its non-interest revenue line is heavily encumbered by partner payments and acquisition costs. **Fifth, the estate in run-off.** All Other contains Legacy Franchises (principally Mexico Consumer/SBMM, i.e. Banamex, plus closed exit and wind-down markets) and Corporate/Other (unallocated corporate costs, Treasury investment activity, transformation spend). It has been a persistent loss centre — USD (4.5) billion net loss in FY2025 — and shrinking it is arithmetically the single largest lever on group returns. ### Revenue model Citi is not a product-mix business in the industrial sense; there is no meaningful licensing or subscription revenue. Revenue is generated in three forms: In 2Q26 net interest income rose 13% and non-interest revenue rose 18% year over year, an unusual configuration for Citi and evidence that the fee businesses are now contributing disproportionately to growth. ### Customers and end-markets Institutional: multinational corporates, financial institutions, asset managers, hedge funds, sovereign and public-sector entities, financial sponsors. Consumer: U.S. cardholders (proprietary and co-brand), U.S. retail deposit and Citigold customers across roughly 650 branches in six metropolitan areas, plus international affluent and high-net-worth clients through four wealth hubs — Singapore, Hong Kong, the UAE and London. End-markets served span essentially the whole of the global economy; the sectors Citi has singled out for targeted growth are digital commerce, technology, healthcare, energy and infrastructure, financial sponsors, and — new in 2025–26 — AI infrastructure, for which Citi has stood up a dedicated banking team.

Disc Medicine is a Watertown, Massachusetts–based clinical-stage biopharmaceutical company built around a single, unusually coherent scientific thesis: that a small number of fundamental control points in red-blood-cell biology — heme biosynthesis and iron homeostasis, mediated by hepcidin — can be pharmacologically tuned in either direction to treat a wide spectrum of haematologic disease. The company operates an in-licensing-and-develop model rather than a discovery-platform model, having assembled its three clinical assets from Roche (bitopertin), AbbVie (selcodebart/DISC-0974 and DISC-0998) and Mabwell Therapeutics (DISC-3405). It has no products approved and no revenue. Its near-term valuation is dominated by a single binary: the Q4 2026 topline readout of the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, which follows a February 2026 Complete Response Letter. Behind that sits a genuine second act in myeloproliferative neoplasms. With approximately $718 million of liquidity at 30 June 2026 and runway into 2029, Disc is unusually well-capitalised for its stage. --- **What the company does.** Disc Medicine discovers, in-licenses, develops and intends to commercialise novel therapeutics for serious haematologic diseases. In the company's own words, repeated verbatim in every press release and in the Compensation Discussion and Analysis of the 2026 proxy statement: *Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.* **Independent characterisation.** Disc is best understood not as a discovery platform company but as a mechanism-directed asset aggregator with deep domain expertise in a single organ system. Management — drawn heavily from Acceleron Pharma, which built a comparable franchise around TGF-β superfamily biology in haematology before its $11.5 billion sale to Merck — has applied a repeatable playbook: identify a de-risked or partially de-risked molecule whose originator has deprioritised it, secure global rights at modest upfront cost with back-loaded milestones, and redirect it into a rare or under-served haematologic indication where the biology is mechanistically obvious and the regulatory path is short. All three clinical assets were sourced this way. Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that Roche advanced through large schizophrenia trials — generating a safety database of more than 4,000 clinical trial participants — before abandoning the CNS indication; Disc licensed it in May 2021 and repositioned it against erythropoietic porphyrias, where reducing glycine supply to developing erythroblasts throttles the accumulation of the toxic photoactive intermediate protoporphyrin IX (PPIX). Selcodebart (DISC-0974), an anti-hemojuvelin monoclonal antibody in-licensed from AbbVie, suppresses hepcidin to liberate iron in anaemia of inflammation. DISC-3405, an anti-TMPRSS6 (matriptase-2) monoclonal antibody in-licensed from Mabwell Therapeutics in January 2023, does the mirror image — inducing hepcidin to restrict iron in diseases of excess erythropoiesis or iron overload. The elegance of the portfolio is that DISC-0974 and DISC-3405 are pharmacological opposites acting on the same axis, giving Disc coverage of both hepcidin-deficient and hepcidin-excess disease states. **Business model and revenue model.** Disc has generated no product, service, subscription or licensing revenue in any fiscal year reported. Its consolidated statements of operations show no revenue line whatsoever for FY2021 through FY2025 and for the six months ended 30 June 2026. The company is financed entirely by equity issuance, supplemented by a term-loan facility from Hercules Capital. The intended revenue model is direct commercialisation: Disc retains worldwide rights to bitopertin and has already built marketing, market access, medical science liaison and field sales infrastructure in the United States in anticipation of launch, a build-out the compensation committee credited as a 2025 corporate achievement. One small out-licensing arrangement exists — a December 2024 out-license of legacy Gemini intellectual property to Oak Bay Biosciences, Inc. — but it is immaterial to the investment case. **Value chain position.** Disc occupies the clinical development and (prospectively) commercial layers only. It owns no manufacturing. Drug substance and drug product are produced by contract development and manufacturing organisations; the 2025 corporate goals explicitly include "initiated CMC technology transfer to Phase 3 CDMO" for both DISC-0974 and DISC-3405, confirming an outsourced supply chain. Clinical trials are run through contract research organisations, a dependency the company identifies as a risk factor. Upstream, Disc is a licensee dependent on Roche, AbbVie and Mabwell for underlying rights; downstream, if approved, bitopertin would be distributed through specialty pharmacy and centre-of-excellence channels typical of ultra-rare disease. **Customer types and end-markets.** Ultimately: haematologists, hepatologists and dermatologists treating protoporphyria at porphyria centres of excellence; haematologist-oncologists treating myelofibrosis and polycythemia vera; and, in later-stage pipeline ambitions, gastroenterologists (anaemia of inflammatory bowel disease) and sickle cell disease specialists. Payers are commercial insurers and CMS in the US, and national reimbursement bodies in Europe. Management commentary at the Wells Fargo healthcare conference in September 2026 indicated a launch strategy focused on engaged, diagnosed patients and centres of excellence — the classic ultra-orphan concentration play.

Macy's, Inc. is the largest operator of conventional department stores in the United States and one of the few remaining scaled multi-format, multi-price-point American retailers. Its portfolio spans three nameplates that deliberately straddle distinct income tiers: Macy's for the middle-to-upper-middle consumer, Bloomingdale's for the premium-contemporary-to-luxury consumer, and Bluemercury for the affluent prestige-beauty consumer. The company is two and a half years into "Bold New Chapter," a transformation that trades scale for productivity — closing roughly 150 unproductive Macy's doors while reinvesting in a "go-forward" fleet of roughly 350 locations, of which 200 receive intensive labour, assortment and visual investment. The economic model is no longer merchandise margin alone: a Citibank credit-card profit-share and the Macy's Media Network retail-media platform together contributed $857 million of high-incremental-margin other revenue in FY2025. Owned real estate of 243 locations provides an unusual asset backstop for a mid-cap discretionary retailer. --- ### The company's own description The FY2025 Form 10-K opens Item 1 as follows in substance: Macy's, Inc. is a premier omnichannel retail organisation operating 665 stores, websites and mobile applications under three iconic brands — Macy's, Bloomingdale's and Bluemercury. It sells apparel and accessories, cosmetics, home furnishings and other consumer goods, and it operates across a spectrum running from value-conscious off-price shoppers to premium luxury consumers. Management characterises the multi-brand, multi-category, multi-channel model as providing flexibility to read and react to shifting consumer demand, and states that the company serves an annual base of nearly 40 million active customers. The filing describes each nameplate in turn. Macy's is presented as a modern department store attracting a broad middle-to-higher-income customer base, operating full-line and smaller-format locations and an off-price concept, Macy's Backstage. Bloomingdale's, founded more than 150 years ago, is described as the upscale, premium-contemporary-to-luxury offer serving an affluent, multigenerational customer through highly curated environments, with full-line stores, the smaller Bloomie's format, the Bloomingdale's The Outlet off-price concept, and licensed international stores in Dubai (United Arab Emirates) and Al Zahra (Kuwait). Bluemercury is described as a luxury beauty and spa services retailer built on a client-first, hyper-personalised service model in neighbourhood locations, weighted toward premium dermatological skincare, clinical treatments and elevated fragrance. ### Independent characterisation Macy's is best understood as four distinct businesses sharing one balance sheet, one supply chain and one credit-card economics engine. The **core Macy's merchandise business** is a structurally shrinking, cash-generative annuity. Net sales inclusive of closures fell 3.8% at the Macy's nameplate in FY2025, yet comparable sales at the go-forward fleet rose 0.6% and at the Reimagine 125 subset rose 1.0%. The strategic bet is that the company can shrink the denominator faster than the numerator declines, arriving at a smaller, higher-productivity chain of roughly 350 doors. The **luxury businesses** are the growth engine and increasingly the equity story. Bloomingdale's grew comparable sales 7.4% in FY2025, 10.2% in Q1 FY2026 and 11.3% in Q2 FY2026, the latter its highest second-quarter sales volume on record. Bluemercury completed its sixth consecutive year of comparable sales growth in FY2025 and accelerated to +6.4% and +6.2% in the first two quarters of FY2026. The **credit-card business** is a profit-share, not a lending book. Under the sixth amendment to the amended and restated Credit Card Program Agreement with Citibank, N.A., signed 13 December 2021 and running to 31 March 2030, Citibank owns the receivables and Macy's receives fees plus a tiered share of portfolio profits net of programme expenses. Credit card revenues, net were $669 million in FY2025 (3.1% of net sales), up 24.6% year on year on portfolio health. Proprietary credit card sales penetration was 40.1% in FY2025 versus 41.6% in FY2024. The **retail media business**, Macy's Media Network, monetises first-party shopper data and on-site inventory across all three nameplates. Net revenue was $188 million in FY2025, up 6.8%, aided by the Amazon Retail Ad Service integration. **Revenue model mix.** Macy's does not report a product/service/subscription split. Derived from disclosed lines, FY2025 revenue was approximately 96.2% merchandise sales (owned inventory plus commissions on licensed departments and marketplace) and 3.8% "other revenue," of which credit card profit-share was 78% and retail media 22%. Merchandise is overwhelmingly owned-inventory retail; the marketplace (third-party sellers) and licensed departments (third-party operated shops such as fine jewellery and certain beauty) contribute only commission revenue to net sales, which is why the company's headline comparable-sales metric is expressed on an "owned-plus-licensed-plus-marketplace" basis while GAAP net sales are not. **Value-chain position.** Macy's sits at the retail tier. It does not manufacture. It sources national brands wholesale and contracts private-brand production, predominantly in Asia (China, Vietnam, India, Indonesia and Jordan are named in the 10-K). It operates its own logistics network of 25 disclosed facilities and its own e-commerce platforms. It is therefore exposed to both wholesale brand-allocation dynamics upstream and to landlord/mall economics downstream. **Customer types and end-markets.** All revenue is business-to-consumer, essentially all in the United States and its territories. End-markets served are women's accessories, shoes, cosmetics and fragrances (42% of FY2025 net sales); women's apparel (22%); men's and kids' (21%); and home and other (15%). Digital was 35% of net sales in FY2025, up from 33% in each of FY2023 and FY2024, and 31% in the seasonally weaker second quarter of FY2026. **Loyalty.** Macy's Star Rewards is a spend-based programme weighted toward proprietary card usage; Bloomingdale's Loyallist and Bluemercury BlueRewards are tender-neutral points programmes. Management describes these as integral to customer lifetime value rather than standalone marketing tools.

Viridian is a fast-follower executed with unusual discipline. It licensed a shelved oncology antibody (AVE-1642) from ImmunoGen, re-engineered the development thesis around thyroid eye disease, and beat a $1.9 billion incumbent on regimen convenience rather than on novel biology. FDA approval of Lumvoa (veligrotug-vvze) on 26 June 2026 — four days ahead of its PDUFA date, and with a label spanning both active and chronic TED — converted a decade of loss-making R&D into a commercial franchise overnight. The company now runs a rare-disease playbook it knows well: a concentrated 2,000-physician prescriber base, an in-house patient-services arm, and a follow-on subcutaneous autoinjector (elegrobart) intended to defend and expand the franchise from 2027. The strategic bet is that IGF-1R remains the dominant TED mechanism long enough for Viridian to build a two-product, self-funding rare-disease company before IL-6, FcRn, oral, and on-body-injector competitors arrive. Viridian Therapeutics, Inc. is a Waltham, Massachusetts–headquartered, newly commercial-stage biotechnology company whose entire enterprise value rests on a single therapeutic mechanism — full antagonism of the insulin-like growth factor-1 receptor (IGF-1R) — applied to a single rare autoimmune indication, thyroid eye disease (TED), with adjacent optionality in neonatal Fc receptor (FcRn) inhibition and thyroid-stimulating hormone receptor (TSHR) blockade. Headcount roughly tripled in two years. Management stated in a June 2026 interview that the organization had passed 400 employees, including approximately 100 newly hired sales representatives; a third-party workforce tracker put the figure at approximately 374 in July 2026. The precise mid-2026 headcount is not disclosed in an SEC filing and the two secondary figures differ. --- **What the company does.** Viridian discovers, engineers, develops, and — as of June 2026 — commercializes monoclonal antibodies and engineered protein fragments for serious and rare autoimmune diseases. Its capabilities, as described in the FY2025 10-K, "span protein and antibody discovery and engineering, biologics manufacturing, nonclinical and clinical development, commercial planning, and commercialization." **The company's own characterization (FY2025 Form 10-K, Item 1).** "We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience." The filing describes a pipeline directed at three validated targets: IGF-1R for TED, FcRn for broad autoimmunity, and TSHR for TED and Graves' disease. Following the Lumvoa approval, the company's boilerplate description shifted to "autoimmune and rare diseases," dropping the earlier "serious and rare diseases" framing — a subtle repositioning toward the larger FcRn opportunity. **Independent characterization.** Viridian is not a discovery-platform company despite its protein-engineering language. It is a *mechanism-arbitrage* company. Every clinical-stage asset targets a receptor whose therapeutic validity has already been established commercially by another party: IGF-1R by Amgen's Tepezza ($1.9 billion 2025 net sales), FcRn by argenx's Vyvgart (~$4.15 billion 2025 net sales), and TSHR by the well-characterized autoantibody biology of Graves' disease. The company's value creation comes from three levers applied to de-risked targets: (i) molecular re-engineering — full versus partial receptor antagonism, half-life extension via Xencor Xtend technology, Fc-fragment and albumin-binding-domain bispecific formats; (ii) regimen compression — five infusions instead of eight, 30–40 minutes instead of 60–90, every-4-week or every-8-week subcutaneous dosing instead of infusion-centre visits; and (iii) label breadth — running separate placebo-controlled Phase 3 studies in *both* active and chronic disease where the incumbent's label rests principally on active-disease data. This is a lower-risk, lower-differentiation model than novel-target discovery: it compresses scientific risk but raises commercial and pricing risk, because the fast follower must win on execution and access rather than on exclusivity. **Business and revenue model.** As of the second quarter of 2026 the company has four current or prospective revenue lines: Revenue mix is therefore transitional. FY2025 revenue of $70.8 million was 98.8% a one-time licensing payment. From FY2026 onward the mix should invert toward product sales, with royalty and milestone income as a secondary layer. Note the DRI arrangement is a *liability*, not revenue: Viridian owes DRI 7.5% of U.S. net sales up to $600 million annually, 0.8% between $600 million and $900 million, 0.25% between $900 million and $2 billion, and nothing above $2 billion. The 7.5% first-tier rate could step up to low double digits if elegrobart is not approved by a specified date — an important embedded penalty. **Value-chain position.** Viridian occupies the discovery-through-commercialization span but outsources manufacturing entirely. It relies on third-party CDMOs — including a five-year non-exclusive Lumvoa supply agreement with WuXi Biologics disclosed in a May 2026 regulatory filing — and on Enable Injections' enFuse on-body system (a $15.0 million upfront paid in Q1 2023) and a commercially validated autoinjector for elegrobart. It has no owned manufacturing plant. Downstream, it sells through the specialty-distribution and buy-and-bill channel typical of infused rare-disease biologics, supported by ViridianCares, its in-house reimbursement and patient-support programme activated at approval. **Customer types and end-markets.** The proximate customers are approximately 2,000 core prescribing physicians in the United States — predominantly oculoplastic surgeons, neuro-ophthalmologists, and endocrinologists — plus hospital outpatient departments and freestanding infusion centres. The economic buyers are commercial payers, Medicare Part B, and Medicaid. The end-market is a U.S. moderate-to-severe TED prevalent population the company estimates at approximately 190,000 patients, with comparable epidemiology in Europe. Ex-U.S. commercial rights are held by Viridian everywhere except Japan (Kissei) and Greater China (Zenas/Zai Lab).

PNC occupies a deliberate and increasingly rare position in U.S. banking: national in reach without the regulatory burden of GSIB status. Since the 2021 BBVA USA acquisition made its branch network coast-to-coast, management has pursued a two-track strategy — organic customer acquisition in high-growth Sun Belt and Mountain West markets, supported by a roughly $2 billion branch build-out, alongside opportunistic in-market consolidation, most recently the $4.3 billion FirstBank transaction that made PNC the leading retail deposit-taker in Denver. The revenue engine is unusually balanced for a regional: a large, sticky commercial treasury-management franchise, a growing capital markets and M&A advisory business housed partly in Harris Williams, and a wealth platform with $602 billion of total client assets. FY2025 delivered record revenue of $23.1 billion, 21% EPS growth and 500 basis points of positive operating leverage. The principal open question is whether scale ambitions can be met without diluting the balance-sheet discipline that has defined the Demchak era. The PNC Financial Services Group, Inc. is a U.S. bank holding company and financial holding company headquartered in Pittsburgh, Pennsylvania. It is the largest U.S. "super-regional" bank that is not designated a global systemically important bank, and it operates the fourth-largest branch network in the United States. At 30 June 2026, following the January 2026 acquisition of FirstBank Holding Company, consolidated assets stood at $616.0 billion. Source: FY2025 10-K Human Capital disclosure for FY2025 (55,333 total; 53,859 full-time and 1,474 part-time, of which 26,168 full-time and 1,427 part-time in Retail Banking). FY2022–FY2024 figures from aggregated annual-report headcount series; the FY2024 figure of 55,184 is consistent with PNC's prior-year disclosure. Headcount fell roughly 10% between FY2022 and FY2024 as post-BBVA integration synergies and the 2023 continuous-improvement programme took effect, then stabilised in FY2025 ahead of the FirstBank acquisition, which added more than 1,620 employees on conversion in June 2026. --- ### What the company does PNC is a diversified financial services holding company. It describes itself in the FY2025 Form 10-K as one of the largest diversified financial institutions in the United States, engaged in retail banking, corporate and institutional banking, and asset management, with most products and services offered nationally. Its retail branch network is coast-to-coast, and it maintains strategic international offices in four countries outside the United States. Substantially all business is conducted through PNC Bank, National Association, supplemented by non-bank subsidiaries engaged in market-making, securities underwriting, advisory services and permissible merchant-banking activities under the Gramm-Leach-Bliley Act. At 31 December 2025 the balance sheet comprised $573.6 billion of consolidated assets, $440.9 billion of deposits and $60.6 billion of total shareholders' equity. By 30 June 2026, post-FirstBank, those figures were $616.0 billion, $449.8 billion and $64.0 billion respectively. ### Revenue model PNC is not a product company; its revenue model is a spread-and-fee hybrid characteristic of a large commercial bank, with the following economics: **Net interest income (62% of FY2025 revenue; $14,410 million).** PNC earns the spread between the yield on interest-earning assets — $327.9 billion average loans and $142.2 billion average securities in 4Q25 — and the cost of funding, dominated by a $439.5 billion average deposit base of which 22% was non-interest-bearing in 4Q25 and 23% in 2Q26. The single most important economic driver over 2024–2026 has been the repricing of fixed-rate assets originated at low pandemic-era yields into higher current-coupon assets as they mature. This produced net interest margin expansion from 2.66% (FY2024) to 2.83% (FY2025) to 2.96% (Q2 2026) without any need for balance-sheet risk-taking. Management has repeatedly characterised this as a mechanical, largely rate-path-independent tailwind. **Fee income (34% of FY2025 revenue; $7,925 million, a non-GAAP measure).** Five disclosed categories: card and cash management ($2,899 million FY2025), asset management and brokerage ($1,597 million), capital markets and advisory ($1,548 million), lending and deposit services ($1,310 million), and residential and commercial mortgage ($571 million). Card and cash management — principally treasury management fees, debit and credit card interchange, and merchant services — is the largest and most annuity-like. Capital markets and advisory is the most cyclical and has been the fastest-growing, up 24% in FY2025 and 80% year-over-year in Q2 2026 on record M&A advisory activity. **Other non-interest income ($764 million FY2025).** Private equity valuation marks, securities gains and losses, and Visa Class B derivative fair-value adjustments. This line is volatile and non-core; Visa-related adjustments were negative $41 million in 4Q25 and negative $85 million in 2Q26, while the 2Q26 Visa Class B-2 exchange produced a one-time $448 million gain. There is no meaningful subscription or licensing revenue. PNC does license and sell technology-enabled services (for example commercial loan servicing and technology solutions through Midland Loan Services, and merchant/POS capability through Linga), but these are reported within the fee categories above rather than separately. ### Value chain position and customer types PNC sits at the intermediation layer of the financial value chain: it originates and holds credit risk, it holds and pays for deposits, and it operates the payment rails and treasury infrastructure that its commercial clients use. Unlike a monoline, it does not depend on a single funding market or a single fee stream. Customer types by segment: ### Independent characterisation PNC is best understood as a deposit franchise with three monetisation layers stacked on top of it. The base layer — a $450 billion, largely relationship-driven deposit book with a 23% non-interest-bearing mix that has been *rising* while peers' has fallen — is the genuine competitive asset. The second layer is a commercial lending and treasury-management franchise that converts those relationships into a recurring, low-capital fee stream of roughly $4.5 billion a year. The third and newest layer is a capital-markets and advisory business that PNC has been deliberately building to raise fee intensity toward money-centre levels; capital markets and advisory revenue grew from $1,250 million in FY2024 to $1,548 million in FY2025 and annualises above $2.0 billion on the Q2 2026 run rate. The strategic logic of the FirstBank deal and the branch build-out is to widen the base of the stack so the upper layers have more to sell into.

RattanIndia Power is a single-asset Indian independent power producer whose economic identity now rests almost entirely on one 1,350 MW subcritical coal-fired station at Nandgaonpeth, Amravati, Maharashtra, selling 1,200 MW into a 25-year Case-1 power purchase agreement with Maharashtra State Electricity Distribution Company Limited (MSEDCL). It is the surviving half of a much larger 2,700 MW ambition: the twin 1,350 MW Sinnar (Nashik) project was lost to insolvency and was formally transferred to a MAHAGENCO–NTPC consortium on 24 February 2026. The company is best understood not as a growth utility but as a post-restructuring cash-flow and litigation-recovery story. Following the December 2019 one-time settlement — in which Goldman Sachs and Värde Partners acquired ₹6,574 crore of principal for ₹4,050 crore — and the FY2024 deconsolidation of Sinnar, the balance sheet carries roughly ₹3,700 crore of borrowings against ₹9,613 crore of assets. Earnings power is capped by a fixed PPA tariff, a single counterparty, and a still-negative reserves position. --- ### What the company actually does RattanIndia Power Limited ("RPL") generates electricity from coal and sells it. That is the whole of the operating business. The company owns and operates the Amravati Thermal Power Plant — five subcritical units of 270 MW each, aggregating 1,350 MW, commissioned in March 2015 at Nandgaonpeth village, Amravati district, Maharashtra. The installed configuration is rated by the company at an annual generation capability of **11,826 million units (MU)**. Approximately 1,200 MW of this capacity is contracted to MSEDCL, the state distribution utility, under long-term power purchase agreements. A residual ~28 MW is sold on merchant terms into the power exchanges. In FY2026 the merchant channel produced 22.19 MU and ₹16.38 crore of revenue — roughly 0.5% of turnover. The dependency is therefore near-total: MSEDCL is not merely the largest customer, it is effectively the only customer. ### The company's own characterisation From the corporate website and results presentations, RPL describes itself as "one of India's largest private power generation companies, with installed capacity of 2,700 MW thermal power plants at Amravati and Nashik (1,350 MW at each location) in Maharashtra, India with investments of Rs. 18,615 crores (US $2.5 Billion)," and lists supporting infrastructure of 2,400 acres of land, 35 km of railway lines and 63 km of water pipelines. Its stated vision is "to be a best-in-class organization responsible for delivering sustainable value to all its stakeholders and contributing to a strong and prosperous New India," with a mission "to be at the forefront of India's energy needs by providing reliable and efficient power solutions." **Analyst caveat.** This self-description is materially stale. The Nashik/Sinnar asset was held through subsidiary Sinnar Thermal Power Limited (STPL, formerly RattanIndia Nasik Power Limited), which was admitted to insolvency in September 2022, deconsolidated in FY2024, and transferred to a MAHAGENCO–NTPC consortium on 24 February 2026. As of this dossier's date, RPL's operating fleet is **1,350 MW, not 2,700 MW**. The website's "2,700 MW" framing and the "₹18,615 crore invested" figure describe historic gross investment across two projects, one of which the company no longer owns. Investors reading the corporate site without cross-checking the FY2026 results will materially overstate the asset base. The company's own Q1 FY27 investor deck correctly leads with "Installed capacity of 1350 MW (270 MW × 5 units)". ### Business model and revenue model RPL operates a **regulated-style long-term contracted generation model** with a two-part tariff, not a product, service, subscription or licensing model. The revenue mix decomposes as follows: The tariff was set through Case-1 tariff-based competitive bidding at a **levellised tariff of ₹3.26/kWh**. Two PPAs underpin the arrangement, dated **22 April 2010 (450 MW)** and **5 June 2010 (750 MW)**, together running to approximately 2040. The critical structural feature is that the tariff allows recovery of the **entire fixed cost provided the plant achieves a normative PAF of 85%**. Fixed-cost recovery is thus an availability game, not a dispatch game — which is why RPL's investor communications lead with PAF and PLF rather than with revenue. ### Value chain position RPL sits at a single node: **generation**. It does not own coal mines (fuel is contracted), does not own transmission of consequence beyond evacuation infrastructure, and does not distribute. Its upstream is Coal India Limited via subsidiary South Eastern Coalfields Limited (SECL), with a Fuel Supply Agreement for **6.10 million metric tonnes** annually (an earlier disclosure cited 5.493 MTPA; the current figure in FY2026 filings is 6.10 MMT). Coal moves by rail over a dedicated ~35 km siding; RPL received and unloaded **1,469 rakes in FY2026** (4.0 per day) and **449 rakes in Q1 FY27** (4.9 per day). Downstream is MSEDCL and, marginally, the Indian Energy Exchange. This narrow position is the source of both the company's stability (contracted offtake, pass-through fuel) and its fragility (no diversification, no ability to reprice, one counterparty). ### Customer types and end-markets There is one direct customer of consequence — MSEDCL, a state-government-owned distribution utility — whose downstream end-market is the residential, agricultural, commercial and industrial electricity consumers of Maharashtra. Secondary customers are exchange counterparties in the day-ahead and real-time markets. There are no international customers, no retail customers, and no channel partners. ### Corporate structure note Yahoo Finance and other aggregators describe RPL as operating "together with its subsidiary, Poena Power Development Limited." The consolidated financial statements for FY2026 continue to be presented on a consolidated basis, and the residual difference between standalone and consolidated results is small (FY2026 consolidated PAT ₹52.44 Cr vs. standalone-derived PBT ₹46.59 Cr; Q1 FY27 consolidated PAT ₹45.85 Cr vs. standalone ₹44.36 Cr), indicating that subsidiary activity is now immaterial to group earnings. A complete current subsidiary register is **not publicly disclosed** in the results filings reviewed; it would require the FY2025-26 Annual Report (circulated to members 2 September 2026).

GoDaddy occupies an unusual and durable position in the internet economy: it is simultaneously the point of first contact for a very large share of the world's new commercial identities and a subscription software company monetising those identities over multi-year lifetimes. Approximately 81 million domains under management — roughly 21% of the world's registered domains — give it the widest funnel in its category, while a customer base of 20.4 million paying accounts with 85% annual retention and ARPU of $242 gives it recurring revenue of $4.34 billion and free cash flow of $1.6 billion. The company has spent the last five years converting a low-margin registrar into a two-segment platform where higher-margin applications and commerce now supply 38% of revenue. The strategic question for 2026 onward is whether agentic AI erodes the value of that funnel or, as management contends, makes trusted naming and identity infrastructure more valuable. GoDaddy is betting capital and credibility on the latter. GoDaddy Inc. is a Delaware holding company, incorporated on 28 May 2014, that operates the world's largest domain name registrar together with an integrated stack of website-building, hosting, security, email, marketing and payments products aimed at microbusinesses and independent entrepreneurs. The operating business traces to 1997, when Bob Parsons founded a Phoenix-area software venture originally named Jomax Technologies, which was rebranded GoDaddy in 1999. The current holding company was created as the vehicle for the March 2015 initial public offering that took the business public following a 2011 leveraged recapitalisation by KKR, Silver Lake and Technology Crossover Ventures. --- ### What the company does GoDaddy sells the components of a commercial online identity to people and organisations that lack the technical resources to assemble those components themselves. The core proposition is a one-stop shop: a customer arrives to search for and register a domain name, and is then progressively sold website building, hosting, security, business-class email, marketing tools, and increasingly payment acceptance and merchant financing, all administered through a single account and supported by a human care organisation. The company itself frames the customer journey around three needs it calls the Entrepreneur's Wheel: **Identity** (company name, domain, logo, email address), **Presence** (website, hosting, social and search visibility, security), and **Commerce** (online and in-person selling, payment processing, invoicing, inventory and order management). This taxonomy is not merely marketing language; it maps directly onto the product architecture and, imperfectly, onto the two reporting segments. The company's own characterisation in its FY2025 Form 10-K is that it is a global leader serving a large market of entrepreneurs by developing easy-to-use one-stop-shop solutions backed by proactive, informed and personalised guidance, with a stated mission of empowering entrepreneurs everywhere and making opportunity more inclusive for all. **Independent characterisation.** GoDaddy is best understood as three businesses bolted onto one distribution engine. First, a low-growth, high-cash, wholesale-plus-margin domain registrar and registry operator with structural exposure to registry price increases it does not control (chiefly VeriSign's .com pricing). Second, a genuinely software-margin applications business — website builders, resold Microsoft 365 seats, marketing tools — that has been the entire growth story for five years. Third, an emerging fintech in the form of GoDaddy Payments, point-of-sale hardware and GoDaddy Capital merchant advances, which carries commerce economics rather than software economics. The domain business is the customer acquisition channel; the other two are where the margin is made. Management's central operating discipline is to convert domain-funnel traffic into attached, higher-priced, longer-lived subscriptions, which is visible in ARPU growth of roughly 30% since 2021 against a flat-to-declining customer count. ### Revenue model Revenue is overwhelmingly subscription and recognised ratably over contract terms, with cash typically collected upfront at contract inception. This produces the two defining features of GoDaddy's financial profile: a very large deferred revenue balance ($3.32 billion at 31 December 2025, current and non-current combined) and free cash flow that structurally exceeds accounting earnings. The revenue mix by nature is approximately: - **Recurring subscription** — domain registrations and renewals, hosting, security, website builders, email seats, marketing plans. Annualised recurring revenue of $4,336.2 million at 31 December 2025, or roughly 88% of total revenue. - **Non-recurring transactional** — aftermarket/secondary domain sales, domain transfers, one-time setup and migration fees, and non-recurring professional website services. Excluded from ARR by definition. This is the source of most quarter-to-quarter revenue volatility, and management has taken to excluding "high-value aftermarket transactions" from guidance entirely. - **Payment processing / take-rate** — GoDaddy Payments revenue recognised on gross payments volume at a processing rate. GPV reached $3.4 billion in 2025, up 31%. - **Resale / partner economics** — Microsoft 365, Titan and Open-Xchange email seats, ProofPoint encryption, Barracuda archiving, and third-party control panels are resold, carrying lower gross margin than proprietary software. - **Wholesale registry** — GoDaddy Registry operates or provides back-end services to approximately 170 TLDs, selling wholesale to third-party registrars. There is essentially no licensing revenue and no hardware business of consequence other than Smart Terminal point-of-sale devices, which are a customer-acquisition vehicle for payments rather than a margin line. ### Value chain position GoDaddy sits between the registries (VeriSign for .com/.net, ccTLD authorities, and — increasingly — itself via GoDaddy Registry) and the end customer. Its cost of revenue is dominated by registry fees paid on domain registrations, which are contractually fixed and periodically increased by the registry operators. This creates a structural gross margin ceiling in the Core segment of roughly 63–64% at the consolidated level, and explains why the entire margin expansion story of the last five years has come from operating leverage on fixed costs and mix shift toward A&C rather than from gross margin improvement. Consolidated gross margin has moved within a 63.0%–64.0% band across all five years reviewed. Downstream, the company partly disintermediates itself: it supplies registration and management infrastructure to other domain registrars and to corporate domain portfolio owners, converting competitors into wholesale customers. ### Customer types The FY2025 Form 10-K identifies four populations: 1. **Independents** — the largest group, comprising microbusinesses and non-commercial ventures, most with fewer than five employees and most self-identifying as having little or no technical or design skill. 2. **WebPros** — website designers and developers building on behalf of others; freelancers, moonlighters and small agencies. They demand technical depth (WordPress, cPanel, Plesk, Drupal, Joomla), reseller economics, client billing and administrative access. 3. **Domain Investors** — individuals and organisations holding portfolios of domains for secondary-market resale. They supply liquidity and inventory to the aftermarket. 4. **Domain Registrars, Third-Party Registrars and Corporate Domain Portfolio owners** — wholesale and enterprise buyers of registration platform, registry services and corporate portfolio management. Concentration risk is negligible: no single customer represented more than 10% of total revenue in any period presented. ### End markets The company markets and sells in over 200 markets worldwide. As of 31 December 2025 approximately 9.8 million customers — 48% of the customer base — were outside the United States, but international customers generated only approximately 33% of revenue, reflecting materially lower ARPU outside the US. No single country outside the US represented more than 10% of total revenue. Management sizes its addressable market by reference to the US Small Business Administration and Census Bureau: approximately 36.2 million US small businesses, representing 99.9% of US firms and an estimated 43.5% of US GDP, with the addressable universe extending beyond businesses to individuals, universities, charities, community organisations and hobbyists. ### Durability metrics *Retention rates are as characterised in the FY2025 Form 10-K, which states retention was approximately 85% in each of the five years ended 31 December 2025 except 2024, when it was approximately 84% owing to divestitures, product migrations and end-of-life decisions. Retention for customers of more than three years' tenure was approximately 90% at 31 December 2025.

Charter Communications is the largest fixed broadband operator in the United States and, following the 19 August 2026 closing of the $34.5bn Cox Communications combination and the Liberty Broadband merger, the largest land-based telecommunications company in the country by locations passed. Operating under the Spectrum brand across a 45-state footprint, the company sells a converged bundle of high-speed internet, mobile (as an MVNO on Verizon's network), video and voice to roughly 37 million customer relationships, supported by an exclusively U.S.-based workforce that management treats as a competitive differentiator. Its economic model is a high-fixed-cost, high-incremental-margin hybrid fibre-coaxial network monetised through subscription relationships, with adjusted EBITDA margins above 41%. The strategic problem it is presently solving is not scale but growth: broadband subscribers have declined for eight consecutive quarters under fixed-wireless and fibre-overbuild pressure, and the equity has de-rated roughly 45% over twelve months even as free cash flow inflects upward. **Share price and market capitalisation (as at 5 September 2026):** CHTR traded at approximately **$151.91**, within a session range of $149.47–$153.66. The 52-week range is **$111.55–$285.82**, with a 52-week average of approximately $196.55. Third-party market-capitalisation estimates for CHTR **conflict materially** because of the company's multi-class, partnership-unit structure: one retail data provider reported ~$26.6bn on 5 Sep 2026; another reported ~$20.4bn as at 18 Aug 2026 (immediately pre-closing); a third reported ~$24.4bn in the same window. The discrepancy arises because Charter's economic equity comprises Class A common stock plus Charter Holdings common units held by Advance/Newhouse Partnership ("A/N") and, since 19 August 2026, by Cox Enterprises, plus $6.0bn of convertible preferred units. On an as-exchanged, as-converted basis the share count is materially higher than Class A shares outstanding. **Investors should compute market capitalisation from the fully diluted, as-exchanged count disclosed in the Q3 2026 Form 10-Q rather than relying on aggregators.** --- ### The company's own description Charter describes itself in its FY2025 Form 10-K and earnings releases as "a leading broadband connectivity company with services available to 58 million homes and small to large businesses across 41 states through its Spectrum brand" (that description predates the Cox closing; the post-closing footprint is 45 states). It states that, "Founded in 1993, Charter has evolved from providing cable TV to streaming, and from high-speed Internet to a converged broadband, WiFi and mobile experience," and that "Over the Spectrum Fiber Broadband Network and supported by our 100% U.S.-based employees, the Company offers Seamless Connectivity and Entertainment with Spectrum Internet®, Mobile, TV and Voice products." Structurally, "Charter is a holding company whose principal asset is a controlling equity interest in Charter Communications Holdings, LLC ('Charter Holdings'), an indirect owner of Charter Communications Operating, LLC ('Charter Operating') under which substantially all of the operations reside." In its 2026 proxy statement the board articulates the operating thesis directly: the company's core initiatives "focus on utilizing our fiber-powered network to deliver high-quality, competitively priced products, with outstanding service, allowing us to increase both the number of customers we serve over our network and the number of products we sell to each customer. This combination also reduces the number of service transactions we perform per relationship, yielding higher customer satisfaction and lower customer churn, which results in lower costs to acquire and serve customers and drives greater profitability." ### Independent characterisation Charter is best understood as a **regional-monopoly-adjacent fixed infrastructure owner that has been forced into a converged-services retailer posture by the erosion of its two historic profit engines.** The asset base is a hybrid fibre-coaxial (HFC) distribution plant passing roughly 58.4 million homes and businesses at 31 December 2025 on a standalone basis, materially expanded by the Cox plant. This is a sunk-cost, long-lived, extremely capital-intensive asset with high replacement cost and, in most of its footprint, one to three credible competing wireline alternatives. The economics are those of a utility: gross incremental margin on an added broadband subscriber approaches 100%, and the entire enterprise value question reduces to (a) how many relationships the plant carries, (b) revenue per relationship, and (c) the maintenance-plus-upgrade capital required to keep the plant competitive. **Revenue model mix.** Charter is overwhelmingly a **subscription services** business. There is essentially no licensing revenue and only modest product revenue. On FY2025 total revenue of $54,774m: - **Recurring residential connectivity subscription** (internet + mobile service): $27,527m — 50.3% of total - **Recurring residential entertainment/legacy subscription** (video + voice): $15,053m — 27.5% - **Recurring commercial subscription** (small business + mid-market/large business): $7,315m — 13.4% - **Advertising** (transactional/cyclical, political-sensitive): $1,468m — 2.7% - **Other** (predominantly mobile device hardware sales, plus processing fees, franchise-related and miscellaneous): $3,411m — 6.2% This mix is the story of the company in one table: the subscription base is intact, but it is **rotating** — from a high-ARPU, high-programming-cost video product toward a lower-ARPU, near-zero-marginal-cost internet-plus-mobile product. Video revenue fell 9.4% in FY2025 while mobile service revenue rose 22.0%. Programming costs fell $831m (8.6%) in FY2025. The rotation is margin-accretive (adjusted EBITDA margin rose from 39.8% in FY2021 to 41.5% in FY2025 despite a revenue CAGR of only 1.46%) but revenue-dilutive. **Value chain position.** Charter occupies the **last-mile access and customer-relationship layer**. Upstream it is a buyer of: programming rights from media companies (Disney, Warner Bros. Discovery, Paramount, NBCUniversal, Fox, AMC Networks); wholesale wireless capacity from Verizon under a long-standing consumer MVNO and, from 2026, from T-Mobile for business wireless; network equipment from vendors including CPE, node and amplifier suppliers; and, since November 2025, AI/cloud infrastructure from Amazon Web Services. Downstream it sells direct to end customers with no meaningful channel intermediation, and it operates a two-sided advertising business monetising its own video inventory. It does **not** own material content assets (it exited most regional sports network ownership exposure) and it does **not** own wireless spectrum at scale — it is a capacity buyer, not a network owner, in mobile. That is a deliberate capital-efficiency choice with a strategic cost: Charter's mobile margins are structurally thinner than a facilities-based carrier's. **Customer types and end markets.** (i) Residential households — 29.6m relationships at 31 Dec 2025; (ii) small business — 2.2m relationships; (iii) mid-market and large business/enterprise — 357,000 primary service units, sold as fibre connectivity, managed network, and managed IT/cloud (the latter capability materially expanded by the Cox commercial fibre and managed-IT businesses acquired in the Equity Sale component of the Cox Transactions); (iv) local, regional and national advertisers; (v) government and institutional customers via subsidised rural build programmes (RDOF and state broadband grants) and community/education commitments.

Shopify is the commercial operating system for independent commerce. It sells a multi-tenant, single-branch cloud platform that lets any merchant — from a first-time entrepreneur on a $5 Starter plan to a global enterprise on Commerce Components — run storefronts, physical retail, wholesale, cross-border and, increasingly, AI-agent channels from one back office. Its economics are a two-sided flywheel: a modest, high-margin subscription annuity (81% gross margin) attaches merchants; a much larger, lower-margin, volume-linked merchant-solutions book (payments, capital, shipping, advertising) monetises their success. In FY2025 the platform facilitated $378.4bn of GMV and converted that into $11.56bn of revenue at a 3.05% take rate, $1.47bn of operating income and $2.01bn of free cash flow, with revenue growth accelerating to 30%. Shopify does not build foundational AI models; it is positioning instead as the merchant-side infrastructure layer for agentic commerce, co-authoring the Universal Commerce Protocol with Google. It is debt-free, founder-controlled, and remote-first. Note: the FY2025 figure of approximately 7,600 is taken directly from the FY2025 Form 10-K. Headcount peaked above 11,000 in 2022 before two reduction programmes (July 2022 and May 2023). --- ### The company's own description (FY2025 Form 10-K, Item 1) Shopify states that it "provides essential internet infrastructure for commerce" and that its "all-in-one platform makes it easier to start, run and grow a business, powering sales online, in store, and everywhere in between." Its stated mission is "to make commerce better for everyone with a platform and services that are engineered for speed, customization, reliability and security, while delivering a better shopping experience for consumers everywhere." The 10-K frames the design principle as merchant sovereignty: "As owners and operators, merchants set their course, while Shopify offers them the tools to seamlessly manage, market and sell their products across various sales channels, including online storefronts, physical retail spaces, AI platforms, social media and more." ### Independent characterisation Shopify is best understood not as e-commerce software but as a **merchant-side payments and financial-services business wrapped in a software distribution mechanism**. The software is the customer-acquisition channel and the retention moat; the money is made on transaction volume. The evidence is in the revenue mix. In FY2025, subscription solutions — the actual software licence — generated $2,752M, or 23.8% of revenue. Merchant solutions — payments, currency conversion, lending, shipping labels, POS hardware, App Store advertising and Shop Campaigns — generated $8,804M, or 76.2%. Merchant solutions grew 35% against subscription solutions' 17%. The ratio has widened every year for a decade: subscription solutions were 29.1% of revenue in FY2021 and are 23.8% now. **The revenue model in four layers:** 1. **Recurring subscription (annuity, ~81% gross margin).** Monthly or annual platform fees plus variable platform fees, POS Pro subscriptions, app and theme sales, and domain registrations. Monthly Recurring Revenue reached $205M at 31 December 2025 and $221M at 30 June 2026, versus $178M at 31 December 2024. 2. **Payments and financial services (volume-linked, ~38% gross margin).** Shopify Payments processing and FX fees are the single largest line. Gross Payments Volume grew 37% in FY2025 and Shop Pay GMV grew 62%. Shopify Capital (sales-based repayment loans and merchant cash advances) sat at $1,784M of loans and MCAs net on the balance sheet at 31 December 2025, up from $1,224M a year earlier — a 46% increase, and the principal driver of the transaction-and-loan-loss provision rising from $227M to $417M. 3. **Attach services (referral and marketplace economics).** Shipping labels, Shopify Markets Pro cross-border, referral fees from partners, advertising on the Shopify App Store, and Shop Campaigns buyer acquisition. 4. **Ecosystem rents.** More than 21,000 apps in the Shopify App Store as at 31 December 2025, with revenue share on paid apps and themes recognised within subscription solutions. **Value chain position.** Shopify sits between the merchant's product/brand layer (which it deliberately does not own — it operates no first-party marketplace and holds no merchant inventory) and the consumer demand layer (Google, Meta, TikTok, ChatGPT, Copilot, physical retail). It is a horizontal infrastructure supplier with an unusually asset-light footprint: FY2025 capital expenditure was $26M on $11,556M of revenue, or 0.22%. Compute is rented, primarily from Google Cloud Platform. Payment rails are rented from Stripe and PayPal — a genuine single-point-of-dependency the 10-K discloses explicitly. **Customer types.** The 10-K notes that "most merchants subscribe to our Basic and Grow plans" while "the majority of our gross merchandise volume has been generated from merchants subscribing to our Shopify Plus plan and enterprise offerings." No single merchant has ever exceeded 5% of total revenues in a reporting period. Merchant geography as at 31 December 2025: 44% United States, 31% EMEA, 16% Asia Pacific/Australia/China, 5% Canada, 5% Latin America. **End-markets.** Apparel and accessories is the dominant vertical, followed by home and garden, beauty and fitness, food and drink, and health. Named brands cited by the company include Aldo, BarkBox, Carrier, Meta, SKIMS, Supreme and Vuori. **Cohort economics.** The 10-K discloses that historical merchant cohorts have grown revenue over time: "growth in revenue from merchants that remain on the Shopify platform has more than offset decreases in revenues from merchants leaving the platform," and "the total annual revenue generated by each of our previous cohorts has grown on a generally consistent basis." This is the structural argument for durability at scale.